Clinical Research

Evaluating the benefits of metformin in metastatic prostate cancer

Pilot study to evaluate the prognostic and metabolic benefits of metformin during androgen deprivation therapy (ADT) in metastatic prostate cancer.

What is the purpose of this research?

Patients with metastatic prostate cancer are usually treated with Androgen Deprivation Therapy (ADT).  Although successful in short term, the cancer usually progresses in few years.  It is thought that the side effects of ADT such as obesity and high levels of insulin contribute towards the treatment resistance.  Metformin is the most commonly used diabetic medication in the world.  It lowers insulin and help patients lose weight.  The purpose of this study is to evaluate whether metformin will help delay the treatment resistance. 

Study Population

Metastatic prostate cancer patients who have not had hormonal treatment, and are scheduled to start Androgen Deprivation Therapy (ADT).

Further Information and Who to Contact

Should you want any further information concerning this project, or if you have any medical problems which may be related to your involvement in the project (for example, any side effects), you can contact

Dr Handoo Rhee, Urologist
phone: +61 7 3176 7957
email: handoorhee@gmail.com

Prof Colleen Nelson, Principal Investigator
phone: +61 7 3176 7443
email: colleen.nelson@qut.edu.au

Dr Maggie Fung, Clinical Coordinator
phone: +61 7 3176 7449

Further information is also available from the Australian New Zealand Clinical Trials Registry (ANZCTR) http://www.ANZCTR.org.au/ACTRN12614001054606.aspx